[关键词]
[摘要]
目的 二十五味余甘子丸联合福辛普利钠治疗原发性高血压的临床效果。方法 选择2017年2月—2019年3月在洪湖市中医医院治疗的原发性高血压患者131例,随机分为对照组(65例)和治疗组(66例)。对照组晨起口服福辛普利钠片,1片/次,1次/d。治疗组在对照组基础上口服二十五味余甘子丸,3丸/次,2次/d。两组患者均治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者血压水平,以及血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平。结果 治疗后,对照组临床有效率为75.38%,显著低于治疗组的92.42%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组舒张压(DBP)、收缩压(SBP)均显著降低(P<0.05),且治疗组血压水平明显低于对照组(P<0.05)。治疗后,两组hs-CRP、TNF-α和IL-6水平均显著降低(P<0.05),且治疗组明显比对照组低(P<0.05)。结论 二十五味余甘子丸联合福辛普利钠治疗原发性高血压可明显降低患者舒张压、收缩压,具有较好的临床疗效,安全可靠。
[Key word]
[Abstract]
Objective To analyze the clinical effect of Ershiwuwei Yuganzi Pills combined with fosinopril sodium in treatment of essential hypertension. Methods Patients (131 cases) with essential hypertension in Honghu Hospital of TCM from February 2017 to March 2019 were randomly divided into control (65 cases) and treatment (66 cases) groups. Patients in the control group were po administered with Fosinopril Sodium Tablets in the morning, 1 tablet/time, once daily. Patients in the treatment group were po administered with Ershiwuwei Yuganzi Pills on the basis of the control group, 3 pills/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure level, and the serum level of hs-CRP, TNF-α and IL-6 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 75.38%, which was significantly lower than 92.42% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the level of DBP and SBP in two groups was significantly decreased (P<0.05), and the blood pressure level in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the serum level of hs-CRP, TNF-α and IL-6 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Ershiwuwei Yuganzi Pills combined with fosinopril sodium in treatment of essential hypertension can significantly reduce the DBP、SBP, which has good clinical efficacy, safety and reliability.
[中图分类号]
R972
[基金项目]